If you are using a GLP-1 drug, your nutritional status should be monitored, not assumed
Nooms own internal data also shows that the likelihood of experiencing side effects increases significantly as dosages increase
A meta-analysis which included eight trials with a total of 60,080 patients found that GLP-1 agonists reduced major adverse cardiovascular events, all-cause mortality and hospital admissions for heart failure in treated patients with type 2 diabetes, regardless of structural homology 20
aRR, adjusted relative risk
Highlights of Prescribing Information: Saxenda (liraglutide) injection, for subcutaneous use
These effects are modest, but they are at least documented